Quick Answer
RHYTHM PHARMACEUTICALS, INC. reported Research And Development Expense of $167.34 million for the year ending 2025.
- RHYTHM PHARMACEUTICALS, INC. showed a decrease of -29.7% in Research And Development Expense from 2024 to 2025.
- This data is from RHYTHM PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2016: $5.42 million | Q1 2017: $4.87 million | Q2 2017: $5.40 million | Q3 2017: $5.97 million | Q1 2018: $12.29 million | Q2 2018: $8.58 million | Q3 2018: $10.71 million | Q1 2019: $22.76 million | Q2 2019: $35.31 million | Q3 2019: $26.57 million | Q1 2020: $22.50 million | Q2 2020: $23.00 million | Q3 2020: $23.00 million | Q1 2021: $19.91 million | Q2 2021: $25.10 million | Q3 2021: $27.54 million | Q1 2022: $32.51 million | Q2 2022: $31.46 million | Q3 2022: $21.12 million | Q1 2023: $37.95 million | Q2 2023: $33.54 million | Q3 2023: $33.57 million | Q1 2024: $128.67 million | Q2 2024: $30.19 million | Q3 2024: $37.93 million | Q1 2025: $36.97 million | Q2 2025: $42.31 million | Q3 2025: $46.03 million.
- Over the full 11 years of available data (2015 to 2025), RHYTHM PHARMACEUTICALS, INC.'s Research And Development Expense has grown by 2,241.1%.
- Historical annual values: Fiscal year 2025: $167.34 million | Fiscal year 2024: $237.96 million | Fiscal year 2023: $134.95 million | Fiscal year 2022: $108.63 million | Fiscal year 2021: $104.13 million | Fiscal year 2020: $90.45 million | Fiscal year 2019: $109.45 million | Fiscal year 2018: $50.34 million | Fiscal year 2017: $22.89 million | Fiscal year 2016: $19.59 million | Fiscal year 2015: $7.15 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: